# Semaglutide: Research Overview — Prime Research Peptides > A literature summary of semaglutide, the FDA-approved GLP-1 receptor agonist: mechanism, weight-loss RCTs, cardiovascular and kidney outcomes, safety profile, and regulatory status. A 31-amino-acid GLP-1 analogue with multiple large outcomes trials behind it — the deepest human evidence on this desk and the reference point for everything else. ## The short version Semaglutide is a peptide medicine, approved by the FDA for type 2 diabetes, weight management, cardiovascular risk reduction in obesity, and (2025) a liver condition called MASH. It works by mimicking a hormone called GLP-1 — which is naturally released after you eat and tells the brain to feel full, the pancreas to release insulin, and the stomach to slow down. The drug was designed to outlast the natural hormone: two small changes to the amino acid sequence and a fatty-acid side chain extend its half-life from about two minutes (native GLP-1) to roughly one week, which is why it can be taken once weekly. That stability was engineered in a laboratory, and the resulting compound has been tested in clinical trials involving tens of thousands of people. On this desk, semaglutide is the lead compound and the evidence benchmark. When people ask how strong the data is for retatrutide or BPC-157, the comparison they should be making is to what semaglutide has achieved: 17,604-person cardiovascular outcomes trials [3], 3,533-person kidney outcomes trials [2], and a direct head-to-head trial against tirzepatide [1]. That is the ceiling. Everything else on this desk is measured against it. ## What it is Semaglutide is a synthetic 31-amino-acid acylated analogue of human GLP-1, sharing approximately 94% sequence homology with the native hormone. Two structural substitutions confer protease resistance: position 8 alanine is replaced by alpha-aminoisobutyric acid (Aib), which blocks degradation by DPP-4; position 34 lysine is replaced by arginine. The remaining lysine at position 26 carries a C18 fatty di-acid side chain via a glutamic-acid/ADO spacer; this lipid moiety drives strong reversible binding to serum albumin, protecting the peptide from renal clearance and metabolism. The result is a half-life of approximately one week, enabling once-weekly subcutaneous injection. An oral formulation co-formulated with the absorption enhancer SNAC also exists, with a bioavailability of ~0.4-1% — low enough that strict fasted administration is required to achieve a therapeutic dose. ## How it works Semaglutide activates the GLP-1 receptor (GLP-1R) — a G-protein-coupled receptor expressed on pancreatic beta cells, intestinal L cells, cardiac tissue, kidney, and, crucially, the brain. The peripheral effects are incretin-class: glucose-dependent insulin secretion from beta cells, glucagon suppression from alpha cells, and delayed gastric emptying. The weight effect is primarily central. Rodent studies showed that semaglutide reaches the hypothalamic arcuate nucleus, area postrema, and parabrachial nucleus via circumventricular organs — brain regions that lack the usual blood-brain barrier protection. There it activates anorexigenic POMC/CART neurons and inhibits appetite-driving NPY/AgRP neurons, suppressing food intake and modifying food preference without lowering energy expenditure [6]. In plain terms: the drug quiets the part of the brain that drives food-seeking. Many patients describe this as "food noise going quiet" — a subjective experience that tracks the pharmacological mechanism. ## What the research shows The human evidence for semaglutide is the largest on this desk. Key trial findings: **Weight management.** STEP 1 randomized 1,961 adults with overweight or obesity (no diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean body-weight change: -14.9% (semaglutide) versus -2.4% (placebo), a treatment difference of approximately 12.4 percentage points [4]. **Head-to-head with tirzepatide.** SURMOUNT-5 enrolled 751 adults with obesity and directly compared maximum-tolerated doses of the two compounds. At 72 weeks, tirzepatide produced -20.2% versus semaglutide's -13.7% — a statistically significant difference favoring the newer compound [1]. **Cardiovascular outcomes.** SELECT enrolled 17,604 adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes. Once-weekly semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke: HR 0.80 (95% CI 0.72-0.90; P<0.001) — a 20% relative reduction versus placebo [3]. **Kidney outcomes.** FLOW enrolled 3,533 people with type 2 diabetes plus chronic kidney disease. Semaglutide 1.0 mg reduced the primary kidney composite (kidney failure, ≥50% eGFR decline, or kidney/cardiovascular death): HR 0.76 (95% CI 0.66-0.88), a 24% lower risk versus placebo [2]. **Cardiovascular safety in type 2 diabetes.** SUSTAIN-6 (n=3,297, high CV risk) established cardiovascular non-inferiority: HR 0.74 (95% CI 0.58-0.95). A notable finding in the same trial: rates of diabetic-retinopathy complications were significantly higher with semaglutide (HR 1.76; 95% CI 1.11-2.78; P=0.02), concentrated in patients with pre-existing retinopathy undergoing rapid HbA1c reduction [7]. ## Reported effects, cautions and safety **Anecdotal community reports (not clinical evidence, not verified):** The most widely described benefit is appetite suppression described as a dramatic quieting of "food noise" — the constant mental loop around eating — often appearing within the first week or two. People also report reduced cravings for sugar and high-fat foods, meaningful weight loss over several months, and (less commonly) reduced interest in alcohol. Adverse effects reported most frequently include nausea (peaking around dose increases and generally easing within a week or two), sulfur burps described as rotten-egg odor tied to slowed gastric emptying, constipation and/or diarrhea that can alternate, fatigue concentrated in the first day or two after injection, and acid reflux. A smaller share reports hair shedding and facial gauntness attributed to rapid weight loss rather than the drug itself. These are **anecdotal, not clinical evidence** — self-reports from patient communities with no controlled verification. **Clinical-trial and label-based cautions:** - *GI intolerance*: Nausea in roughly one-third of patients in pooled analyses; the dominant reason for discontinuation. Predominantly mild-to-moderate and transient, concentrated during dose escalation [5]. - *Thyroid C-cell tumors (boxed warning)*: Derived from rodent studies at supratherapeutic exposures. A personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication; no clear human MTC signal has been established [5]. - *Diabetic retinopathy*: SUSTAIN-6 found significantly higher retinopathy-complication rates (HR 1.76) in patients with pre-existing retinopathy undergoing rapid glycemic correction [7]. Monitor when glycemia is corrected rapidly. - *Biliary disease*: An increased risk of cholelithiasis versus placebo, attributed largely to the magnitude and rate of weight loss [5]. - *Lean-mass loss*: Body-composition substudies show a meaningful proportion of weight lost is lean rather than fat mass, raising sarcopenia concerns especially in older adults. - *Weight regain on stopping*: STEP 1 extension and STEP 4 both show substantial weight regain after discontinuation, framing this as a chronic rather than curative intervention. - *Pregnancy*: Contraindicated. A washout of approximately two months before planned conception is advised given the roughly one-week half-life. - *Compounded semaglutide*: During the FDA-declared shortage, compounded products generated documented dosing errors and hospitalizations; after the shortage was resolved in 2025, compounding pathways were curtailed [5]. ## Where it fits Semaglutide is the most evidence-dense compound on this desk — the one that has been through 17,000-patient cardiovascular outcomes trials and a direct head-to-head comparison against its successor [3][1]. Its place on the evidence spectrum is approved, multi-indication, and thoroughly characterized in large controlled human populations. That context is important when reading the other compounds here. Tirzepatide is also approved and has comparable trial depth, but is newer. Tesamorelin is approved for a narrow indication only. Retatrutide is investigational — its Phase 2 data are impressive, but it has not cleared the regulatory review that semaglutide has. BPC-157 is at the preclinical end of the spectrum entirely [23]. See the full [evidence map](/compare) for where all five compounds sit against each other. ![Semaglutide research illustration](/images/semaglutide.webp) --- An independent literature desk mapping the evidence from regulatory approval to first-in-human pilot — a spectrum, not a sales pitch.